Thomas A. Miller

发表

Histone deacetylases and cancer: causes and therapies

P. Marks, V. Richon, R. Rifkind, 2001, Nature Reviews Cancer.

SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

C. Kenific, Melissa Chenard, A. Kral, 2008, Bioorganic & medicinal chemistry letters.

Design of novel histone deacetylase inhibitors.

A. Kral, Karin M. Otte, Thomas A. Miller, 2007, Bioorganic & medicinal chemistry letters.

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Joshua Close, Sriram Tyagarajan, C. Kenific, 2008, Bioorganic & medicinal chemistry letters.

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

C. Kenific, Melissa Chenard, A. Kral, 2014, ACS medicinal chemistry letters.

Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).

J. Grimm, Melissa Chenard, A. Kral, 2009, Bioorganic & medicinal chemistry letters.

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Jessica E. Bolden, R. Dickins, S. Minucci, 2013, Molecular Cancer Therapeutics.

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

Melissa Chenard, A. Kral, B. Haines, 2008, Bioorganic & medicinal chemistry letters.

Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.

C. Kenific, Melissa Chenard, A. Kral, 2009, Bioorganic & Medicinal Chemistry Letters.

Potent benzoazepinone γ-secretase modulators with improved bioavailability.

C. Kenific, A. Szewczak, C. Moxham, 2015, Bioorganic & medicinal chemistry letters.

Histone deacetylase inhibitors: development as cancer therapy.

P. Marks, V. Richon, Thomas A. Miller, 2004, Novartis Foundation symposium.

Benzo[b]thiophene-based histone deacetylase inhibitors.

R. Mosley, Thomas A. Miller, J. Secrist, 2007, Bioorganic & medicinal chemistry letters.

Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.

I. Kariv, C. Moxham, Thomas A. Miller, 2012, Bioorganic & medicinal chemistry letters.

Purine derivatives as potent gamma-secretase modulators.

C. Kenific, A. Szewczak, J. Crispino, 2010, Bioorganic & medicinal chemistry letters.

Derives du benzothiophene

Karin M. Otte, Thomas A. Miller, J. Methot, 2006 .

Patent status of histone deacetylase inhibitors

Thomas A. Miller, 2004 .

The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.

A. Kral, A. Szewczak, A. Hitz, 2007, Bioorganic & medicinal chemistry letters.

Histone deacetylase inhibitors.

Thomas A. Miller, D. Witter, David J Witter, 2003, Journal of medicinal chemistry.

Nonclinical Safety Assessment of the Histone Deacetylase Inhibitor Vorinostat

S. Galloway, V. Richon, Thomas A. Miller, 2010, International journal of toxicology.

Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.

M. P. Baker, T. Baillie, K. Koeplinger, 2007, Drug metabolism letters.

Histone deacetylase inhibitors.

P. Marks, V. Richon, Thomas A. Miller, 2004, Advances in cancer research.

Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.

V. Richon, Thomas A. Miller, J. Secrist, 2007, Bioorganic & medicinal chemistry letters.

Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.

R. Hendrickson, C. Paweletz, Fanyu Meng, 2008, Journal of proteome research.

Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors.

A. Kral, B. Haines, Thomas A. Miller, 2014, Biochemistry.

Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.

M. Crackower, H. Houshyar, Hongshi Yu, 2013, American journal of respiratory cell and molecular biology.

Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).

J. Grimm, A. Kral, A. Szewczak, 2008, Bioorganic & medicinal chemistry letters.

Histone deacetylases and cancer: causes and therapies

P. Marks, V. Richon, R. Rifkind, 2001, Nature Reviews Cancer.

Histone deacetylase inhibitors.

P. Marks, V. Richon, Thomas A. Miller, 2004, Advances in cancer research.